Abstract
Introduction Patients with cancer are prone to develop thromboembolic and atherothrombotic events. Advances in anti-cancer therapies lead to prolonged cancer-specific survival, putting patients at increasing risk of major adverse cardiovascular events (MACE). Hence, tools to personalize risk stratification to predict and eventually prevent cardiovascular complications in patients with cancer are an unmet medical need. Here, we aimed to assess the predictive utility of cardiovascular biomarkers in a representative population of oncologic patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
